The Headline Gap: 28.3% vs 14.9%
The retatrutide vs Wegovy comparison stops being a contest the moment you look at the Phase 3 numbers. On May 21, 2026, Eli Lilly released TRIUMPH-1 topline data from 2,339 adults with obesity: retatrutide 12 mg produced a mean weight loss of 28.3% at 80 weeks. Wegovy’s STEP-1 trial, published in the New England Journal of Medicine in February 2021, reported 14.9% at 68 weeks in 1,961 participants. That is not a marginal gap. That is nearly double the weight loss, from a drug that has not even reached pharmacy shelves yet. A 250-pound person loses roughly 37 pounds on Wegovy and roughly 70 pounds on retatrutide. The difference is roughly the size of an entire adult beagle.
Why Retatrutide Hits Harder: Three Receptors vs One
The mechanistic gap explains the efficacy gap better than any marketing slide. Wegovy (semaglutide 2.4 mg, made by Novo Nordisk in Denmark) binds only the GLP-1 receptor. It slows gastric emptying by roughly 30-40% — measured via acetaminophen absorption studies — and suppresses appetite through the hypothalamus. That is its full toolkit. It works, but it works within a single lane.
Retatrutide (LY3437943, developed by Eli Lilly in Indianapolis) does everything Wegovy does through its GLP-1 component, then adds two more layers. GIP receptor agonism enhances insulin sensitivity and reduces inflammatory adipokine release from visceral fat. Glucagon receptor agonism directly increases resting energy expenditure by 8-12% and drives hepatic fat oxidation. Dr. Ania Jastreboff, the Yale endocrinologist who led the retatrutide Phase 2 trial published in NEJM in June 2023, described the glucagon component as “a metabolic gear that semaglutide simply does not engage.” The SURMOUNT-2 trial showed that retatrutide-treated patients maintained significantly higher resting energy expenditure than predicted by weight loss alone — meaning the glucagon component prevents the 200-400 calorie per day metabolic adaptation that typically sabotages diet-induced weight loss.
The Sub-Responder Story That Matters
Not everyone responds the same way to either drug. In STEP-1, 32% of Wegovy participants achieved 20% or greater weight loss. In TRIUMPH-1, 62.5% of retatrutide 12 mg participants lost at least 25% of body weight, and 45.3% lost 30% or more. Nearly half the retatrutide group hit numbers that historically belonged to Roux-en-Y gastric bypass. Among participants with severe obesity — BMI of 40 or higher — 37.5% of the retatrutide group dropped below BMI 30. That is a population most clinicians considered surgery-only.
Tirzepatide (Zepbound) sits between the two: SURMOUNT-1 reported 22.5% mean weight loss at 72 weeks on the 15 mg dose. Retatrutide beats it by roughly 6 percentage points at 80 weeks. Even the lowest tested retatrutide dose — 4 mg — hit 19% at 80 weeks, which already surpasses Wegovy. The 9 mg dose landed at 25.9%. Every dose of retatrutide beats Wegovy. The only question is by how much.
TRIUMPH-1 Changed the Benchmark
TRIUMPH-1 is the third positive Phase 3 readout for retatrutide, following TRIUMPH-4 (28.7% in obesity with knee osteoarthritis, December 2025) and TRANSCEND-T2D-1 (type 2 diabetes, March 19, 2026, showing HbA1c reductions of 1.7 to 2.0 percentage points). But TRIUMPH-1 is the most consequential because it tests the broad obesity-without-diabetes population — the exact group where Wegovy has dominated since 2021.
What the 104-Week Extension Tells Us
Lilly tracked 532 participants with a baseline BMI of 35 or higher through a 104-week extension. The 12 mg group reached 30.3% mean weight loss at two years — roughly 85 pounds. No approved anti-obesity drug has ever crossed the 30% threshold in a controlled pivotal trial. Participants switched from placebo to retatrutide mid-trial lost 19.2% in just 24 weeks, confirming that the drug produces rapid results even after long delays in starting treatment. Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine in Chicago, noted that “Phase 2 effect sizes in obesity medicine have historically shrunk by 2 to 4 percentage points when replicated in larger Phase 3 populations.” Retatrutide’s Phase 2 results (24.2% at 48 weeks in 338 participants) did not shrink — they grew to 28.3% in Phase 3. That is unusual in obesity pharmacology.
The Side Effect Trade-Off You Need to See
Both drugs belong to the GLP-1 class, so they share the gastrointestinal side effect profile. Nausea is the most common complaint. In TRIUMPH-1, 42.4% of participants on retatrutide 12 mg reported nausea versus 14.8% on placebo. In STEP-1, roughly 44% of Wegovy participants reported nausea. The rates essentially match, but the context is not the same — retatrutide’s nausea comes with roughly double the weight loss. Vomiting hit 25.3% on retatrutide 12 mg versus 4.8% on placebo. Diarrhea: 32% versus 13.5%. Constipation: 26.1% versus 10.9%. These are uncomfortable numbers, but they are predictable and manageable with proper titration.
The Heart Rate Question
Retatrutide’s glucagon receptor activation raises resting heart rate by 5-8 beats per minute on average. Wegovy shows minimal heart rate elevation. This is a real physiological trade-off. For most people, a 5-8 bpm increase is clinically insignificant. For someone with pre-existing tachycardia or certain cardiac conditions, it matters. The dedicated cardiovascular outcomes trial — TRIUMPH-Outcomes with roughly 10,000 patients, running for 3-4 years — will answer whether this matters for hard endpoints like myocardial infarction and stroke. No one has that answer yet. Until that data arrives, the heart rate elevation is a genuine limitation that clinicians and patients need to weigh.
Dysesthesia: The Signal That Got Quieter
The most-watched safety concern coming into TRIUMPH-1 was dysesthesia — abnormal skin sensations like tingling, numbness, or a crawling sensation. In TRIUMPH-4 (December 2025), 20.9% of the 12 mg group reported it versus 0.7% on placebo. TRIUMPH-1 reported a lower rate: 12.5% at 12 mg versus 0.9% on placebo. The difference likely reflects population composition — TRIUMPH-4 enrolled older participants with knee osteoarthritis and more comorbidities, which may have heightened sensory symptom awareness. Lilly reported that most dysesthesia events were mild to moderate and resolved during ongoing treatment. Wegovy has no dysesthesia signal at all, which is an advantage for Wegovy. But the retatrutide data looks more manageable than the December 2025 readout initially suggested, and the absolute risk difference versus placebo was roughly 11-12 percentage points in both trials.
Discontinuation Rates: The Honest Metric
11.3% of retatrutide 12 mg participants stopped due to adverse events versus 4.9% on placebo. At the 4 mg dose — which still produced 19% weight loss, beating Wegovy — discontinuation was close to placebo. Wegovy’s STEP-1 discontinuation due to side effects was approximately 7%. If you are sensitive to GI side effects, the 4 mg retatrutide dose is probably the smarter start than Wegovy’s 2.4 mg fixed dose, because it delivers better results with fewer adverse events.
Wegovy’s One Real Advantage (And It Is Not Efficacy)
Wegovy is FDA approved. Retatrutide is not. That single fact determines every practical difference between these two drugs right now.
Wegovy received fda approval for chronic weight management in June 2021 for adults with a BMI of 30 or greater (or 27 with at least one weight-related comorbidity). The indication extended to adolescents aged 12 and older in December 2022. Wegovy is available by prescription at any pharmacy in the United States. The list price is roughly $1,350 per month, though insurance coverage is common and most patients pay significantly less through manufacturer savings programs. Wegovy has five years of real-world safety data from millions of patients — the kind of post-market surveillance that retatrutide physically cannot have yet.
Retatrutide’s earliest realistic FDA approval is late 2027 to early 2028. Lilly plans a New Drug Application submission in late 2026 to Q1 2027. Standard FDA review takes 10-12 months. Priority Review could compress that by roughly 4 months but has not been confirmed for retatrutide. Until then, retatrutide is only available through Eli Lilly clinical trials or through grey market research vendors. Grey market vials cost $60 to $120 per 10 mg, but carry no regulatory oversight, no purity guarantees, and no dosing standards. The trial results do not transfer to those products. Buying grey market retatrutide after reading TRIUMPH-1 is a misunderstanding of what the data means.
Novo Nordisk also holds a practical edge in insurance coverage. Wegovy sits on most major pharmacy formularies. A new drug from a different manufacturer requires new insurance negotiations, new prior authorization workflows, and new out-of-pocket structures. Even after retatrutide wins FDA approval, it will take 12-24 months for payer coverage to match Wegovy’s current access. The access gap is real, and it will persist even after the FDA says yes.
The Bottom Line on Retatrutide vs Wegovy
Retatrutide is the superior drug by every efficacy metric that exists. The mechanism is broader. The weight loss is roughly double. The responder rates are higher across every threshold. Even the lowest effective dose of retatrutide beats Wegovy’s maximum approved dose. Wegovy’s advantages are all about access — it is FDA approved right now, it is on formularies, and it has a safety database spanning millions of patients over five years.
If FDA approval matters to you and you need a prescription today, Wegovy is your only real option. If you can enter one of Lilly’s ongoing clinical trials and want the best possible weight loss outcome, retatrutide is the clear choice. If you want the honest assessment: retatrutide destroys Wegovy on efficacy, but it does not exist yet as a real drug you can buy from a pharmacy. That will change in 2028. Until then, Wegovy wins on availability but loses on every other axis. The only interesting question is how retatrutide will compare to whatever Novo Nordisk launches next — CagriSema, which showed 22.7% in REDEFINE-1 — but that is a comparison for another article.
Key Numbers at a Glance
- Retatrutide 12 mg (TRIUMPH-1, 80 wk): 28.3% mean weight loss, ~70 lbs
- Wegovy 2.4 mg (STEP-1, 68 wk): 14.9% mean weight loss, ~37 lbs
- Retatrutide 4 mg (TRIUMPH-1, 80 wk): 19.0% — already beats Wegovy
- Retatrutide 12 mg (TRIUMPH-1, 104 wk): 30.3% mean weight loss, ~85 lbs
- Participants losing ≥30% on retatrutide: 45.3%
- Participants losing ≥15% on Wegovy: ~50%
- Participants reaching BMI <30 on retatrutide 12 mg: 65.3%
- Earliest retatrutide FDA approval: Late 2027 to early 2028
- Wegovy list price per month: ~$1,350
- Grey market retatrutide per 10 mg vial: $60-$120 (no quality guarantee)
Leave a Reply